Researchers find

Psilocibine, the main psychoactive ingredient of magical mushrooms, could relieve depression for at least five years after a single dose, according to a new study.

The research, presented on June 18 at the Psychedelic Science 2025 conference in Denver, followed with patients who had been diagnosed with clinical depression, also known as a major depressive disorder (MDD) and had participated in a previous study study with Psilocibina in 2020.

“Most of the people who participated in our essay reported improvements in the intensity of the symptoms of depression or in the ways in which they experienced depression in their lives, which lasted up to five years after the trial,” Fox News Digital, co -author of the study, Alan Davis, director of the Ohio State University Psychedelic Drug Center.

Psychedelic as a potential mental health treatment are explored by Trump administration

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that the result talks about the “exciting” potential of psilocibine and other psychedelic -based treatments in the treatment of MDD and other mental health conditions.

“The results of the study are certainly encouraging,” Drysdale, who did not participate in the study.

Previous studies indicated the possibility of psilocybin as a potential antidepressant, which led to researchers performing the first random clinical trial.

The initial trial of 2020, published in Psychiatry, included 24 patients with major depressive disorder. Half received psilocibine at the beginning of the test and the other half received treatment eight weeks later.

Each patient also suffered 11 hours of psychotherapy.

What is cetamine therapy? Mormone reality stars offer controversial treatment

One month after treatment, 17 patients reported to relieve symptoms. Fourteen of those who denounced the complete remission of depression, according to the published study.

“The effectiveness of psilocibine therapy after a few or few administrations represents another substantial advantage over the antidepressants required by the daily administration,” the researchers wrote.

The new study aimed to explore the long -term effects of this treatment on 21 of the original participants of the trial.

Sixty-seven percent stated that depression five years after treatment, and also had less anxiety and daily operation.

“The study does not take into account the naturalistic changes that could have affected its depression during the five years following the main trial.”

For those who returned, many still denounced lasting benefits in their attitudes, perspectives and ability to pursue things that were significant to them, Davis told Fox News Digital.

“Certainly, a more controlled and rigorous study is required, but at least anecdotally, these findings are very interesting and I am optimistic in terms of the extended effective potential that provides this type of treatments,” added Drysdale.

Other factors may also have played a role in the long -term mental health benefits of participants, such as psychotherapy sessions or other antidepressants, coincided with experts.

“The study does not take into account the naturalistic changes that could have affected its depression during the five years following the main trial, and the sample is not representative of the population of people suffering from depression,” Davis told Fox News Digital.

Parkinson’s patients taking “magic mushrooms” see key advantages, findings of the study

The psilocibine has also been explored as a potential treatment for post-party depression (PPD), which affects up to one in seven new mothers.

A 2022 study stated the potential role of psychedelic in PPDs, and found that the psilocybin has been shown to catalyze a sense of “reconnecting” in new mothers.

Click here to register -you are in our health newsletter

“This effect on the PPD, encouraging a feeling of” reconnection “for the mother, can improve maternal state of mood and baby sensitivity, which can positively affect the satisfaction of maternal role and maternal relationship,” researchers stated.

In February, Cleveland Clinic reported on a nearby study that explores the unique dosing psilocybin as a way to treat the PPD.

The judgment, now in its second phase, focuses on Re104, a medicine similar to the psilocibine.

Participants in the study will undergo multiple physical and mental health tests.

Potential risks and limitations

Ryan Moss, head of Filament Health Sciences, a natural psychedelic medicine development company in the clinical phase in Canada, emphasized the importance of administering psychedelic in a safe environment in treating mental health conditions.

For more health items, visit www.foxnews.com/health

“Psychedelic experiences can sometimes have anxiety, hallucinations and paranoia,” Moss in Fox News Digital told.

Experts recommend that medical experts have to carefully manage the therapeutic use of psychedelic.

“Some patients who use traditional psychedelic have reported by experiencing adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended that participants in clinical trials be prepared and exhaustive by professionals trained during the sessions.

Dr. Marc Siegel, Clinical Professor of Medicine at Nyu Langone Medical Center and Senior Medical Analyst of Fox News, he previously interviewed two of the country’s leading researchers on psychedelic: Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research from MT. Sinai in New York, and Dr. Charles Marmar, Director of the PTSD Research Program by Nyu Langone.

Click here to get the Fox News app

“They agree that there is a therapeutic potential if carefully studied under a very strict medical orientation, but there is a great disadvantage in terms of non -regulated recreational uses,” said Siegel in Fox News Digital at that time.

“Both doctors see a probable therapeutic value for psychedelic if handled carefully Medical experts“, Added Siegel.

Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed to reporting.